Build status - In Progress

HELIOS- A:A Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients with Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)

HELIOS- A:A Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients with Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)
Recruiting
18 years - 85 years
All
Phase 3
164 participants needed
1 Location

Brief description of study

The purpose of this study is to evaluate the efficacy and safety of vutrisiran (ALN-TTRSC02) in patients with hereditary transthyretin amyloidosis (hATTR amyloidosis). Participants will receive vutrisiran or the reference comparator patisiran during the Treatment Period.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Hereditary Transthyretin Amyloidosis,hATTR Amyloidosis
  • Age: 18 years - 85 years
  • Gender: All

Male or female ; 18 to 85 years of age ; Has a diagnosis of hATTR amyloidosis with transthyretin (TTR) mutation;

Updated on 04 Aug 2024. Study ID: 832041

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center